Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Confirmed? or just a realistic assumption?
https://curaegis.com/newsroom/news/update-curaegis-has-officially-sold-off-its-fluid-power-division
ROCHESTER, NEW YORK— (December 7, 2020) – CurAegis Technologies (OTC:CRGS) is pleased to announce the completion of the sale of its Aegis division assets to Poseidon Fluid Power, LLC. Included in the sale are the patents, trademarks, and other intellectual property as well as testing equipment, prototypes, and other fixed assets related to the Aegis division.
Poseidon Fluid Power acquired the assets of the Aegis division (formerly Torvec) pursuant to an Asset Purchase Agreement and Technology Transfer and Assignment Agreement dated December 3, 2020. Terms of the transaction were not disclosed; however, CurAegis will benefit from the successful commercialization of the Aegis assets via royalty payments for a period of ten years.
Jim Donnelly, President and CEO of CurAegis Technologies, stated “The strategic divestiture of the Aegis assets allows CurAegis to pivot our business strategy to focus our resources and efforts exclusively on delivering our innovative SaaS product, Cardian.io, to the rapidly growing mHealth market. We are confident that Poseidon has the right team to advance this technology and look forward to participating in that success consistent with the terms of the agreement.”
Mark Redding, President of Poseidon Systems and Managing Member of Poseidon Fluid Power added, “CurAegis, and its predecessor Torvec, have a long history of innovation in specialty industrial applications in Rochester. Poseidon Fluid Power is excited to leverage our expertise in delivering innovative products to commercialize this platform globally while creating jobs here in Rochester, NY."
A little about Poseidon....
Poseidon Systems is a spinoff from Impact Technologies, a company founded in 1999, and acquired by Sikorsky Aircraft in 2011. Impact Technologies specialized in developing innovative technologies for enabling Condition Based Maintenance (CBM) for critical military assets including drivetrains for air vehicles, Army ground vehicles, and Navy ships.
Since 2010, Poseidon Systems has been a leading innovator in developing and manufacturing real-time condition monitoring solutions, specifically fluid diagnostics. We provide end-to-end solutions for enabling online oil condition and metallic wear debris monitoring resulting in less downtime and reduced opex and maintenance costs for our customers.
The past few days are an anomaly, there is significant interest in the stock yet it has traded sideways and consolidated for the past month. Aka the company is selling a shit load of shares to the market preventing the stock from making a big pop that the retail interest should be creating.
CEO of Robinhood said tonight on Mad Money that INO is the number one stock on their platform recently. That’s a scary thought, huge interest in the stock yet it barely moves. It’s clear that they are diluting the hell out of this stock. If it has that much interest as of lately the stock should be skyrocketing not just moving up slowly. I suspect the upward movement today was speculation that INO might get a grant similar to the MRNA just got from the government. I guess we shall see.
App takes 30 days of monitoring to get “more insights” I guess we’ll have to see.
App launching this week, and huge technology show with CES, does Curaegis have a booth at CES?
Curaegis was recently awarded a patent on an “Alertness Prediction System and Method”
https://pdfpiw.uspto.gov/.piw?Docid=10238335&homeurl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526p%3D1%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-bool.html%2526r%3D1%2526f%3DG%2526l%3D50%2526co1%3DAND%2526d%3DPTXT%2526s1%3DCuraegis%2526OS%3DCuraegis%2526RS%3DCuraegis&PageNum=&Rtype=&SectionNum=&idkey=NONE&Input=View+first+page
https://www.otcmarkets.com/stock/CRGS/quote
Click the link, quite clear it’s now listed as PINK - in big pink letters
Does anyone know the status of the pump patents? I’ve been in this for over 10 years and don’t recall them mentioning new patents filed on the pump. Are the 20 year utility patents nearing expiration, hence it’s easier for a manufacturer to just wait it out vs license it?
Is it possible they failed to keep some type of filing current?
So we are now listed on OTC Pink Sheets, weren’t we on a different market recently OTCBB or something? Last week I was able to get Level 2 quotes through OTC on their site, a few days ago it stopped working. Today I noticed it is now listed as a Pink sheets stock, is that due to the market cap drop? Anyone know?
Damn you! Lol I got sooooo excited when I saw the post preview. April Fools is in 3 months.
On the subject of the watch, is it possible it was written off because they intent to sell the company and didn’t feel it would add anything? Does CRGS own any intellectual property related to the watch?
FDA Officially Denied
Sent: Tue Nov 27 2018 9:32:46 AM EST
BusinessWire, GlobeNewswire and PR Newswire News
BioElectronics Corp BIEL:OTC Pink - Current Information
BioElectronics Announces FDA Market Clearance Update
GlobeNewswire
9:31 AM ET
via NEWMEDIAWIRE -- BioElectronics Corporation (OTC Pink: BIEL), the maker of non-invasive electroceutical devices, announced that the U.S. Food & Drug Administration (FDA) declined the company's 510(k) submission for ActiPatch(R), intended for seeking expanded over-the-counter (OTC) indications for the treatment of musculoskeletal pain. In the back pain study that was submitted to the FDA as clinical evidence, the ActiPatch was found to have a significant treatment effect in women, but only a mild treatment effect in men. Since gender differences in treatment effects were not identified in prior ActiPatch clinical studies (knee and plantar fasciitis pain), the FDA concluded that the clinical evidence in the current 510(k) application was "not substantially equivalent" to the prior evidence.
The medical community acknowledges that there are gender differences in responses to pain therapies [1], and importantly, that women experience pain more intensely than men [2]. Moreover, women are at a greater risk of using opioids than men to combat chronic pain [3]. Given the risks inherent with opioid use, as well as limited efficacy of other pharmacotherapy options such as NSAID's and topicals, there is a dire need for a safe and effective non-pharmacological pain therapy like ActiPatch. Gender-level analysis of the prior ActiPatch clinical data revealed that there indeed were differences in treatment effects between men and women, with women reporting more pain relief than men. The company intends to leverage these findings and resubmit the 510(k) application for a more specific indication: relief of musculoskeletal pain for women. Our sales data are compatible with the observation that women get substantial relief in that about 70% of our sales are to w omen.
Sree Koneru, VP of Product Development, expressed confidence in this strategy, both from a regulatory and marketability perspective. "We are also diligently proceeding with 510(k) applications for US market clearance of postoperative pain (RecoveryRx(R)) and menstrual pain (Allay(R))," he added.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch(R) Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx(R) Devices for chronic and post-operative wound care; Allay(R) Menstrual Pain Therapy; and HealFast(R) Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
References
[1] Bartley, E. J. et.al.;, "Sex differences in pain: a brief review of clinical and experimental findings," Br J Anaesth. , vol. 111, no. 1, pp. 52-58, 2013.
[2] Rettner, Rachel;, January 2018. [Online]. Available: https://www.scientificamerican.com/article/women-feel-pain-more-intensely/.
[3] Serdarevic, mirsada et.al.;, "Gender differences in prescription opioid use," Curr Opin Psychiatry. , " Curr Opin Psychiatry. , vol. 30, no. 4, pp. 238-246, 2017.
Contact: Paul Knopick 940.262.3584 pknopick@eandecommunications.com https://resource.globenewswire.com/media/99ac74c2-fe4b-4e40-93bf-dcbb108b59d0/small/60483-bioelectronis-jpg.jpg
Business Wire is a registered trademark of Business Wire. GlobeNewswire is a registered trademark of The NASDAQ OMX Group, Inc. PR Newswire is a registered trademark of PR Newswire Association, Inc.
Please do not reply to this e-mail from Markit On Demand. Markit On Demand and TD Ameritrade are separate unaffiliated companies and are not responsible for each other's service. For questions regarding your brokerage account, please contact TD Ameritrade Client Services at 1-800-669-3900.
To stop receiving this alert from TD Ameritrade, please click here to update your subscription settings. You may also unsubscribe from all of your alerts using the link above. As always, you can manage all of your alert settings by logging into your TD Ameritrade account and navigating to Research & Ideas > Alerts.
I’m wondering if someone was trying to test the market makers to see if those share blocks on the ask were real or if they’re just spoon feeding the market with computer controlled blocks. While scalp day trading with large share blocks, I have personally wiped out asks causing an increase in price. The bid then follows the ask up to the next price point. You can then put a sell order in above the bid and make a few hundred dollars from the new spread. This can be done over and over again to slowly walk a price up. Sometimes I would try wiping out the ask, the order would fill and then magically the number of shares on the ask would remain the same, clearly a computer was manipulating the ask. In this morning’s quick jump, my guess is some of the MMs fell asleep at the wheel and didn’t have their orders ready when the market opened, the computers quickly caught it and we are back to status quo.
As long as they need to sell more shares at around .33 to raise money to operate, I don’t see the share price advancing much further beyond that. Any big players can just buy into a capital raise at .33 or whatever they were selling at. Big money isn’t going to buy into this open market until it’s out and proven. We need big money to move the price.
They must have subletted part of the building to another company!
Funny you say that about 15 cents I was looking at my cost averaging yesterday and yes I really wish I bough more than 5000 shares at .1522. Who knew
Please ask when the IPhone/Apple Watch Combo will be available. Very interested in trying it on my Apple watch.
CRGS needs a Social media campaign that targets their anticipated customers. You can target key words, interests, age ranges and geographical locations. Get that social media following up amongst the correct audience and they will help grow the interest to their friends simply by sharing posts on Facebook.
I was looking through my cost averaging last night and man do I regret not buying more at .15 in 2015 I bought like 1000 shares at that price, wish I bought 100,000
I prefer to look at it as 14k shares bought at .65 not sold
CAT could easily purchase or license CRGS technology to use in an updated / next generation device. Hopefully they are working with CAT on both the pump and watch. Maybe CAT will just buy the company if they like the products of both divisions! (I can dream)
https://www.macrumors.com/2017/05/10/apple-beddit-sleep-technology/
This could be good or bad for us
The article that mentions the Army and watch was not meant to have any affiliation with Mycadian it was posted simply to show more proof that this technology has a demand with great market potential. At no point was it mentioned at all in the article or by me that it has something to do with Curaegis.
https://www.firerescue1.com/fire-chief/articles/2031999-Firefighter-sleep-7-ways-to-improve-your-crews-sleep-and-safety/
Scroll down toward the bottom #7
7. Look ahead to new technology to help manage sleep and performance. The Army is currently developing a wristwatch-style sleep monitor for all soldiers that will monitor sleep/wake cycles and can be directly linked to predicted performance. They expect these devices to be standard issue gear by 2020.
Warren Buffett explains why he's investing in a risky tech sector: wearables
http://www.cnbc.com/2017/02/08/warren-buffett-berkshire-hathaway-wearables-era.html?__source=facebook
You may still be onto something. Some brokers may restrict market orders on stocks under $1. Now that we have crossed $1 it's very possible that someone placed a market order.
HOLY SHIT $1.91 just traded WTF is going on!?!?!?
Does anyone know the current float / outstanding share? I've been in this for 6 years, so far this week has been incredible, the only 2 stocks that I'm long in have had excellent news and have huge potentials for upswing!
BIEL & CRGS ready to fly!
STOP THE PRESSES!!!! We have hit $1.00
Correct me if I'm wrong, but isn't "NITE" usually detrimental to the share price of penny stocks? It has been my experience in the past that NITE will allow the stock to tick up while they are shorting the entire time knowing that the bottom is going to fall out. With them on the bid and the amount of short shares traded Friday we may be in for a wild ride. I hope I'm wrong.
Scottrade showing $.79, I've had a $.75 alert set for quite a while now and it was great to get that text message. I'm finally safely in the black again after almost 5 years!
So I know I'm completely dreaming here, but the 2014 C7 Corvette is to be unveiled on 01/13/13 (pretty close to the middle of Jan). The retired Corvette Chief Engineer is on the Torvec board... Ok somebody smack me and wake me up now.
"TOVC - Torvec Inc shown over the last 7 trading days and has a 88% pattern match with the Head and Shoulders pattern."
http://www.deepmarket.com/headandshoulders.php
This product looks identical to those of BIEL. I wondering how those patents are doing.
The stock hit over $2/share on news of Kaplan and several other new board members. I do not see how $5 will even be hard to reach on actual commercialization even if it is in the after market. The float has not changed in the past 2 years. Yes the company has issued more preferred shares but the public shares have remained steady.